Syncom Formulations (India) Limited (NSE:SYNCOMF)

India flag India · Delayed Price · Currency is INR
11.30
+0.13 (1.16%)
Apr 2, 2026, 3:29 PM IST
Market Cap10.62B -29.4%
Revenue (ttm)5.03B +28.6%
Net Income689.58M +76.2%
EPS0.70 +75.0%
Shares Outn/a
PE Ratio15.40
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,988,425
Average Volume1,878,402
Open11.00
Previous Close11.17
Day's Range10.72 - 11.50
52-Week Range10.21 - 23.49
Beta0.52
RSI42.76
Earnings DateMay 30, 2026

About NSE:SYNCOMF

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, an... [Read more]

Sector Healthcare
Founded 1988
Employees 744
Stock Exchange National Stock Exchange of India
Ticker Symbol SYNCOMF
Full Company Profile

Financial Performance

In fiscal year 2025, NSE:SYNCOMF's revenue was 4.65 billion, an increase of 76.55% compared to the previous year's 2.63 billion. Earnings were 494.35 million, an increase of 95.28%.

Financial Statements